Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK files two-dose Cervarix in EU

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline has filed for EU approval of a two-dose schedule for its cervical cancer vaccine Cervarix (human papillomavirus bivalent (types 16 and 18) recombinant). The application seeks to allow its administration at zero and six months in girls aged between nine and 14 years for the prevention of pre-malignant genital lesions and cervical cancer causally related to certain HPV types.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts